These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 16622984)
1. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors. Bushnell D J Gastrointest Surg; 2006 Mar; 10(3):335-6. PubMed ID: 16622984 [No Abstract] [Full Text] [Related]
2. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; de Herder WW; Krenning EP Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418 [TBL] [Abstract][Full Text] [Related]
3. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807 [TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608 [TBL] [Abstract][Full Text] [Related]
5. Targeted radiotherapy with radiolabeled somatostatin analogs. Nicolas G; Giovacchini G; Müller-Brand J; Forrer F Endocrinol Metab Clin North Am; 2011 Mar; 40(1):187-204, ix-x. PubMed ID: 21349419 [TBL] [Abstract][Full Text] [Related]
6. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]
7. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas]. Banzo J; Abós MD; Prats E; García F; Razola P Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088 [No Abstract] [Full Text] [Related]
8. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303 [TBL] [Abstract][Full Text] [Related]
9. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531 [TBL] [Abstract][Full Text] [Related]
10. Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm. Zhang J; Kulkarni HR; Singh A; Baum RP Clin Nucl Med; 2018 Sep; 43(9):676-678. PubMed ID: 30080185 [TBL] [Abstract][Full Text] [Related]
11. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653 [TBL] [Abstract][Full Text] [Related]
12. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Forrer F; Mueller-Brand J; Maecke H Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):511-2; author reply 513. PubMed ID: 15688195 [No Abstract] [Full Text] [Related]
13. Peptide receptor imaging and therapy. Kwekkeboom D; Krenning EP; de Jong M J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002 [TBL] [Abstract][Full Text] [Related]
14. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786 [TBL] [Abstract][Full Text] [Related]
15. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687 [No Abstract] [Full Text] [Related]
16. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W Oncology; 2022; 100(3):131-139. PubMed ID: 35078191 [TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Bodei L; Pepe G; Paganelli G Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546 [TBL] [Abstract][Full Text] [Related]
18. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. Savelli G; Bertagna F; Franco F; Dognini L; Bosio G; Migliorati E; Rodella C; Biasiotto G; Bettinsoli G; Minari C; Zaniboni A; Ferrari C; Tomassetti P; Ferrari V; Giubbini R Cancer; 2012 Jun; 118(11):2915-24. PubMed ID: 22020784 [TBL] [Abstract][Full Text] [Related]
19. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236 [TBL] [Abstract][Full Text] [Related]